Stanton Hon Lung Kok

Stanton Hon Lung Kok

Auto-generated profile, based on publicly available information

Stanton Hon Lung Kok

School of Biomedical Sciences, The Chinese University of Hong Kong, P. R. China

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SKStanton Hon Lung Kok
Stanton Hon Lung Kok
Roberto GAMBARIRoberto GAMBARI
Roberto GAMBARI
CCChung Hin Chui
Chung Hin Chui
MYMarcus Chun Wah Yuen
Marcus Chun Wah Yuen
ELEva Lin
Eva Lin
ACAlbert Sun Chi Chan
Albert Sun Chi Chan

20 December 2012 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SCSau Hing Chan
Sau Hing Chan
CCChung Hin Chui
Chung Hin Chui
SCShun-Wan Chan
Shun-Wan Chan
SKStanton Hon Lun Kok
Stanton Hon Lun Kok
DCDessy Chan
Dessy Chan
JTJohnny Cheuk-on Tang
Johnny Cheuk-on Tang

21 March 2012 in Soft Matter
Verified
Journal Article
Closed access
PDF file
PLPik-Ling Lam
Pik-Ling Lam
Kenneth LeeKenneth Lee
Kenneth Lee
SKStanton Hon-Lung Kok
Stanton Hon-Lung Kok
GCGregory Yin-Ming Cheng
Gregory Yin-Ming Cheng
XTXiaoming Tao
Xiaoming Tao
RWRaymond Wong
Raymond Wong
The safety issues of biomedical applications have been a major concern in recent years. Drug delivery associated with microencapsulation technology has been focused on as microencapsulated drugs are believed to promote comparative therapeutic efficiency on human absorption and prolong the life cycle of drugs. The most commonly applied crosslinker is formaldehyde in a gelatin microencapsulation system, which is considerably toxic to the human body. To reduce the risks involved when using formaldehyde, agar was associated with gelatin as the wall matrix materials of microcapsules as it could crosslink with gelatin to give a gel network in the microcapsules formation. Here we report the development, characterization and safe use of agar–gelatin microcapsules. We further demonstrate that both oral and topical applications are possible using the berberine HCl and gallic acid loaded microcapsules respectively. Microcapsules containing both drugs were prepared combining the optimal parameters identified. The mean drug loading efficiency and the mean particle sizes of the berberine HCl loaded microcapsules were 78.16% and 16.75 μm respectively, while those of gallic acid loaded microcapsules were 70.28% and 21.98 μm respectively. The compositions and surface morphology of berberine HCl and gallic acid containing microcapsules were examined using Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM). The in vitro controlled release models demonstrated that the drugs could be gradually released from the microcapsules. The minimum inhibitory concentrations (MICs) and anti-Staphylococcus aureus activity also proved that the berberine HCl loaded microcapsules exhibited better antibacterial activity towards Staphylococcus aureus when compared with those of the original drugs. The in vitro drug delivery model also demonstrated the delivery of berberine HCl from microcapsule treated textiles into nude mice skin. The in vivo mice disease model also showed that gallic acid loaded microcapsules were helpful in the treatment of acute liver and kidney toxicity after an overdose administration of acetaminophen. The development of agar–gelatin microcapsules was demonstrated to be an efficient, deliverable tool for both oral and topical applications.

16 December 2013 in Dalton Transactions
Verified
Journal Article
Closed access
PDF file
PLP.-L. Lam
P.-L. Lam
GLG.-L. Lu
G.-L. Lu
KHK.-M. Hon
K.-M. Hon
KLK.-W. Lee
K.-W. Lee
CHCheuk-Lam Ho
Cheuk-Lam Ho
Wai-yeung WongWai-yeung Wong
Wai-yeung Wong
A series of ruthenium(II) bis(2,2′-bipyridyl) complexes containing N-phenyl-substituted diazafluorenes (Ru-C1, Ru-C6, Ru-C7 and Ru-F) was synthesized and their potential antibacterial activity against methicillin resistant Staphylococcus aureus (MRSA) was investigated. The Ru-C7 complex showed significant improvement in both minimum inhibitory concentration (MIC, 6.25 μg mL−1) and minimum bactericidal concentration (MBC, 25 μg mL−1) towards MRSA when compared with those of methicillin (positive control) (MIC = 25 μg mL−1 and MBC = 100 μg mL−1). The Ru-C7 complex possessed much stronger antibacterial effects than the Ru-C6 complex (MIC, 25 μg mL−1, MBC, >100 μg mL−1). Both Ru-C6 and Ru-C7 complexes were also demonstrated to be biologically safe when tested on normal human skin keratinocytes.

1 July 2004 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
XJXian Jia
Xian Jia
XLXingshu Li
Xingshu Li
WLWing Sze Lam
Wing Sze Lam
SKStanton H.L Kok
Stanton H.L Kok
LXLijin Xu
Lijin Xu
ACAlbert S.C Chan
Albert S.C Chan

1 August 2009 in Phytomedicine
Verified
Journal Article
Closed access
DHDesmond Kwok Po Hau
Desmond Kwok Po Hau
Roberto GAMBARIRoberto GAMBARI
Roberto GAMBARI
RWRaymond Wong
Raymond Wong
MYMarcus Chun Wah Yuen
Marcus Chun Wah Yuen
GCGregory Yin Ming Cheng
Gregory Yin Ming Cheng
DFDavid Wang Fun Fong
David Wang Fun Fong